L

I

LANG , Istvan

Last name: LANG

First name: Istvan

2017 (v1)

Publication

Metadata-only

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

von Minckwitz, Gunter Procter, Marion de Azambuja, Evandro

Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. In this trial, we investigated whether...

Uploaded on: April 14, 2023
2019 (v1)

Publication

Metadata-only

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients

Lambertini, Matteo Campbell, Christine Bines, José

Background: In premenopausal patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, and the prognostic effect of treatment-related amenorrhea (TRA) is unknown. Methods: In the Adjuvant Lapatinib and/or Trastuzumab Treatment...

Uploaded on: March 27, 2023